Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC): A rapid autopsy report of metastatic renal cell carcinoma

American Journal of Surgical Pathology

Volumn 38, Issue 4, 2014, Pages 567-577

  Udager, Aaron M ^a   Alva, Ajjai ^b   Chen, Ying Bei ^d   Siddiqui, Javed ^b   Lagstein, Amir ^a   Tickoo, Satish K ^d   Reuter, Victor E ^d   Chinnaiyian, Arul M ^a,b,c   Mehra, Rohit ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

HLRCC; Rapid autopsy; Renal cell cancer

Indexed keywords

TUMOR MARKER;

ARTICLE; AUTOPSY; CASE REPORT; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LEIOMYOMATOSIS; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; UTERUS CANCER;

AUTOPSY; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LEIOMYOMATOSIS; MIDDLE AGED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 84896640772     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000127     Document Type: Article

References (36)

1. Rubin MA, Putzi M, Mucci N, et al. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res. 2000;6:1038-1045.
2. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res. 2004;64:9209-9216.
3. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;8:393-406.
4. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448:595-599.
5. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008;68:3584-3590.
6. Mehra R, Kumar-Sinha C, Shankar S, et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res. 2011;17:3924-3932.
7. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239-243.
8. Embuscado EE, Laheru D, Ricci F, et al. Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther. 2005;4:548-554.
9. Singhi AD, Cimino-Mathews A, Jenkins RB, et al. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol. 2012;25: 378-387.
10. Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: Update on clinical and molecular characteristics. Fam Cancer. 2011;10:397-411.
11. Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol. 1973;53:409-416.
12. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA. 2001;98:3387-3392.
13. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406-410.
14. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73: 95-106.
15. Linehan WM, Rouault TA. Molecular pathways: Fumarate hydratase-deficient kidney cancer: Targeting the Warburg effect in cancer. Clin Cancer Res. 2013;19:3345-3352.
16. Bardella C, El-Bahrawy M, Frizzell N, et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol. 2011; 225:4-11.
17. Merino MJ, Torres-Cabala C, Pinto P, et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31: 1578-1585.
18. Garg K, Tickoo SK, Soslow RA, et al. Morphologic features of uterine leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome: A case report. Am J Surg Pathol. 2011;35:1235-1237.
19. Sanz-Ortega J, Vocke C, Stratton P, et al. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol. 2013;37:74-80.
20. Nagai R, Brock JW, Blatnik M, et al. Succination of protein thiols during adipocyte maturation: A biomarker of mitochondrial stress. J Biol Chem. 2007;282:34219-34228.
21. Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet. 2006;43:523-526.
22. Refae MA, Wong N, Patenaude F, et al. Hereditary leiomyomatosis and renal cell cancer: An unusual and aggressive form of hereditary renal carcinoma. Nat Clin Pract Oncol. 2007;4:256-261.
23. van Spaendonck-Zwarts KY, Badeloe S, Oosting SF, et al. Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: Implications for surveillance. Fam Cancer. 2012;11:123-129.
24. Weiss L, Harlos JP, Torhorst J, et al. Metastatic patterns of renal carcinoma: An analysis of 687 necropsies. J Cancer Res Clin Oncol. 1988;114:605-612.
25. Esnakula AK, Naab TJ, Green W, et al. Extensive peritoneal carcinomatosis secondary to renal cell carcinoma with sarcomatoid and rhabdoid differentiation. BMJ Case Rep. 2013. [Online article].
26. Lehtonen HJ, Blanco I, Piulats JM, et al. Conventional renal cancer in a patient with fumarate hydratase mutation. Hum Pathol. 2007; 38:793-796.
27. Toubaji A, Al-Ahmadie HA, Fine SW, et al. Clinicopathologic features of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) encountered as sporadic kidney cancer. Mod Pathol. 2013;26:252A-252A.
28. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135:92-109.
29. Tong WH, Sourbier C, Kovtunovych G, et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell. 2011;20:315-327.
30. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res. 1995;55: 658-662.
31. Leroy X, Zini L, Buob D, et al. Renal cell carcinoma with rhabdoid features: An aggressive neoplasm with overexpression of p53. Arch Pathol Lab Med. 2007;131:102-106.
32. Shehata BM, Stockwell CA, Castellano-Sanchez AA, et al. Von Hippel-Lindau (VHL) disease: An update on the clinico-pathologic and genetic aspects. Adv Anat Pathol. 2008;15:165-171.
33. Mourad WA, Nestok BR, Saleh GY, et al. Dysplastic tubular epithelium in "normal" kidney associated with renal cell carcinoma. Am J Surg Pathol. 1994;18:1117-1124.
34. Yorukoglu K, Aktas S, Mungan MU, et al. Tubular dysplasia and carcinoma in situ: Precursors of renal cell carcinoma. Urology. 1999;53:684-689.
35. Van Poppel H, Nilsson S, Algaba F, et al. Precancerous lesions in the kidney. Scand J Urol Nephrol Suppl. 2000;136-165.
36. Zhou C, Yool AJ, Nolan J, et al. Armanni-Ebstein lesions: A need for clarification. J Forensic Sci. 2013;58(suppl 1):S94-S98.